Loading...
•
Dec 31, 2023
Bausch Health Q4 2023 Earnings Report
Bausch Health announced fourth-quarter and full-year 2023 results, with Q4 revenues up 10% on a reported basis and 4% on an organic basis.
Key Takeaways
Bausch Health reported a 10% increase in fourth-quarter revenues, reaching $2.41 billion, and a net loss attributable to Bausch Health of $39 million. Full-year revenues were $8.76 billion, up 8% from the previous year, with adjusted EBITDA at $869 million for the quarter, up 6% from previous year.
Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic basis
Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic basis
Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic basis
Adjusted EBITDA Attributable to Bausch Health Companies Inc. of $869 million for the quarter, up 6%
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Revenue by Segment
Bausch + Lomb/International Revenue
CapyFin.comSalix Revenue
CapyFin.comDiversified Products Revenue
CapyFin.com Forward Guidance
The Company updated its full-year revenue and Adjusted EBITDA (non-GAAP) guidance:
Positive Outlook
- Revenues (in Billions) $9.300 – $9.550
- BHC (excl. B+L) Revenues (in Billions) $4.700 – $4.850
- B+L Revenues (in Billions) $4.600 - $4.700
- Organic growth vs. Prior Year 2%-5%
- Adjusted EBITDA (in Billions) $3.20 - $3.35
Revenue & Expenses
Visualization of income flow from segment revenue to net income